PRAGUE, Czechia—Using a pulmonary artery pressure (PAP) monitor on top of best medical care results in significant improvements in quality of life and “substantial” reductions in heart failure (HF) ...
CardioMEMS ran into a regulatory roadblock last week, when an FDA advisory panel recommended that the agency not approve the company's Champion HF Monitoring System. The device is said to be the first ...
MONITOR-HF is the third randomized, controlled trial globally to show a significant health benefit for indicated heart failure patients CardioMEMS is a paperclip-sized sensor that can remotely flag to ...
In the first randomized clinical trial of remote pulmonary artery pressure–guided monitoring and management of chronic heart failure (HF) in Europe, the intervention "substantially" improved quality ...
Abbott Laboratories, Inc. ABT presented new data from an investigator-sponsored European study — MONITOR-HF. The study revealed that Abbott's CardioMEMS HF System led to a significant improvement in ...
December 8, 2011 (Gaithersburg, Maryland) — An FDA advisory panel collectively decided a tiny pulmonary-artery (PA) pressure monitor for patients with heart failure (HF) isn't ready for prime time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results